Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a large drop in short interest in January. As of January 31st, there was short interest totalling 1,370,000 shares, a drop of 21.3% from the January 15th total of 1,740,000 shares. Based on an average trading volume of 3,200,000 shares, the short-interest ratio is currently 0.4 days.

Institutional Trading of Aethlon Medical

A number of hedge funds have recently added to or reduced their stakes in AEMD. Boothbay Fund Management LLC acquired a new stake in Aethlon Medical in the fourth quarter valued at approximately $186,000. Virtu Financial LLC acquired a new position in shares of Aethlon Medical during the fourth quarter worth $81,000. Sassicaia Capital Advisers LLC acquired a new position in shares of Aethlon Medical during the fourth quarter worth $31,000. Allegiance Financial Group Advisory Services LLC acquired a new position in shares of Aethlon Medical during the fourth quarter worth $26,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Aethlon Medical during the fourth quarter worth $25,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

Aethlon Medical Trading Down 2.5 %

NASDAQ AEMD opened at $0.62 on Friday. The firm has a market capitalization of $8.59 million, a price-to-earnings ratio of -0.22 and a beta of 1.88. The firm’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.48. Aethlon Medical has a 1 year low of $0.24 and a 1 year high of $1.85.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.09. On average, equities research analysts forecast that Aethlon Medical will post -1.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on AEMD shares. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Aethlon Medical in a research report on Thursday, January 30th. StockNews.com started coverage on shares of Aethlon Medical in a research report on Monday, January 27th. They set a “sell” rating on the stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.